Iporel (Clonidine Hydrochloride)

Clonidine is an alpha‑2 adrenergic agonist used in several cardiovascular and neuro‑behavioral conditions.

• Hypertension: reduces systolic and diastolic blood pressure by decreasing sympathetic outflow, useful in essential hypertension management.
• Attention deficit hyperactivity disorder (ADHD): improves attention and reduces hyperactivity as an adjunctive therapy in patients who respond inadequately to stimulants.
• Opioid withdrawal: mitigates autonomic symptoms such as sweating, tachycardia, and anxiety during detoxification from opioids.
• Tobacco cessation: assists in reducing withdrawal symptoms and cravings in nicotine dependence.

• Clonidine selectively stimulates central alpha‑2 adrenergic receptors in the brainstem, which inhibits sympathetic neuronal firing. This reduces norepinephrine release, leading to decreased peripheral vascular resistance, lower heart rate, and ultimately a reduction in arterial blood pressure.

Clonidine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dry mouth: reduced salivary secretion causing throat discomfort.
• Sedation: feeling of drowsiness or fatigue.
• Dizziness: light‑headed sensation, especially when standing.
• Constipation: slowed gastrointestinal motility.
• Headache: mild to moderate pain.
• Fatigue: overall lack of energy.

Serious or Rare Side Effects

• Severe hypotension: dangerously low blood pressure requiring medical attention.
• Bradycardia or heart block: markedly slow heart rate or conduction abnormalities.
• Depression or hallucinations: mood changes or perceptual disturbances.
• Allergic reactions: rash, swelling, or anaphylaxis.
• Syncope: sudden loss of consciousness.
• Renal impairment: worsening kidney function in susceptible individuals.

When prescribing clonidine, clinicians should observe several safety measures to minimize risk.

• Blood pressure monitoring: check blood pressure regularly after initiation and dose changes.
• Dose adjustment in renal impairment: reduce dose in patients with reduced kidney function.
• Caution in depression: monitor for worsening mood or suicidal thoughts.
• Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension.
• Contraindication: hypersensitivity to clonidine or any component of the formulation.
• Store at room temperature: keep in original container, protect from moisture and light.

Clonidine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Beta‑blockers: combined use may cause excessive bradycardia and hypotension.
• Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of profound blood pressure reduction.
• Central nervous system depressants (e.g., opioids, benzodiazepines): may enhance sedation and respiratory depression.
• MAO inhibitors: can precipitate severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase clonidine plasma levels.
• Alcohol: can potentiate sedative effects and dizziness.
• Tricyclic antidepressants: additive hypotensive effect, monitor blood pressure.